Literature DB >> 29694951

Vanishing 17-Hydroxyprogesterone Concentrations in 21-Hydroxylase Deficiency.

Thomas Reinehr1, Juliane Rothermel1, Andreas Wegener-Panzer2, Michaela F Hartmann3, Stefan A Wudy3, Paul-Martin Holterhus4.   

Abstract

We present a boy with a genetically proven congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. While massively elevated 17-hydroxyprogesterone (17-OHP) concentrations after birth led to the diagnosis, 17-OHP concentrations became immeasurable starting with the second year of life even though the dose of hydrocortisone was continuously decreased to ∼7 mg/m2/day. Furthermore, 17-OHP levels were immeasurable during the ACTH test and after withdrawing hydrocortisone medication. In contrast, ACTH levels increased after cessation of hydrocortisone treatment suggesting complete primary adrenal cortex failure. We discuss this case based on the differential diagnosis of complete adrenal cortex failure including other genetic causes in addition to CAH, prednisolone treatment, autoimmune adrenalitis, adrenoleukodystrophy, CMV infection, and adrenal hemorrhage infarction. The most likely disease in our boy is autoimmune adrenalitis, which is difficult to prove years after the onset of the disease. Treatment of CAH had masked the classical symptoms of complete adrenal cortex insufficiency leading to delayed diagnosis in this case.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  17-Hydroxyprogesterone ; Adrenal cortex insufficiency ; Autoimmune adrenalitis ; Congenital adrenal hyperplasia ; Hypoglycemia

Mesh:

Substances:

Year:  2018        PMID: 29694951     DOI: 10.1159/000487927

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  1 in total

1.  Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.

Authors:  Sigrid Aslaksen; Paal Methlie; Magnus D Vigeland; Dag E Jøssang; Anette B Wolff; Ying Sheng; Bergithe E Oftedal; Beate Skinningsrud; Dag E Undlien; Kaja K Selmer; Eystein S Husebye; Eirik Bratland
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-27       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.